close

Enter

Log in using OpenID

Carcinoid Syndrome Diarrhea Treatment Market

embed
Carcinoid syndrome is caused by secretion of certain harmful chemicals by carcinoid tumors.
Carcinoid Syndrome
Trends And Growth
Diarrhea
Treatment
Market
Carcinoid syndrome is caused by secretion of certain harmful chemicals by carcinoid tumors.
Carcinoid syndrome may occur due to infection or other related diseases, and medical or
surgical treatments such as anesthesia, chemotherapy, embolization, and tumor debulking. The
key symptoms of the syndrome include flushing of the skin and diarrhea, rapid heartbeat, and
bronchoconstriction. If remained undiagnosed, it could lead to several complications such as
weight loss, electrolyte imbalance, dehydrations, menopause, irritable bowel disease, and
asthma. For instance, in 2009, a study by Journal of Clinical Oncology, showed 4 to 5 out of
every 100,000 people are diagnosed with a neuroendocrine tumor and over 100,000 people
suffering from neuroendocrine tumor in the U.S., also most individual suffering from carcinoid
are asymptomatic until the tumor is fully developed. To overcome the carcinoid crisis,
treatment options may considered such as surgery, chemotherapy, targeted radionuclide therapy,
radiofrequency ablation, and chemoembolization on the basis of patient-by-patient. Carcinoid
syndrome being a rare condition, there are very few if any treatment options available. This in
turn, creates a highly lucrative opportunities for market players.
      :
https://www.coherentmarketinsights.com/insight/request-pdf/1216
Report includes chapters which deeply display the following deliverable about industry :
• Carcinoid Syndrome Diarrhea Treatment Market Research Objective and Assumption
• Carcinoid Syndrome Diarrhea Treatment Market Purview - Report Description, Executive
Summary, and Coherent Opportunity Map (COM)
• Carcinoid Syndrome Diarrhea Treatment Market Dynamics, Regulations, and Trends Analysis Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Carcinoid Syndrome Diarrhea Treatment Market, By Regions
• Carcinoid Syndrome Diarrhea Treatment Market Competition by Manufacturers including
Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and
Product Type.
• Carcinoid Syndrome Diarrhea Treatment Market Manufacturers Profiles/Analysis including
Company Basic Information, Manufacturing Base and Its Competitors.
• Carcinoid Syndrome Diarrhea Treatment Market Manufacturing Cost Analysis including Key
Raw Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Carcinoid Syndrome Diarrhea Treatment Market Forecast including Production, Consumption,
Import and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
       :
By Treatment Type:
• Chemotherapy
• Oral Therapy
• Somatostatin Analog (SSA) Therapy
By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
 -       

In February 2017, Lexicon Pharmaceutical Inc., announced that the U.S. Food and Drug
Administration (FDA) approved Xermelo (Telotristat etiprate) as the first and only orally
administered therapy for the treatment of carcinoid syndrome diarrhea in combination with
somatostatin analog therapy (SSA) for adults. Xermelo mainly targets the overproduction of
serotonin hormone inside mNET cells and reduces the frequency of carcinoid syndrome diarrhea.
Furthermore, in 2017, Ipsen Biopharmaceutical, announced the U.S. Food and Drug
Administration (FDA) approval for a supplemental indication of Somatuline Depot (lanreotide)
Injection 120 mg for the treatment of carcinoid syndrome, to reduce the frequency of shortacting somatostatin analogue rescue therapy.
Development of first-of-its-kind therapeutic approach to treat carcinoid syndrome diarrhea
creates highly lucrative growth opportunities for market players. However, low awareness and
certain side effects associated with this therapy are expected to hinder growth of the carcinoid
syndrome diarrhea treatment market.
         

According to the National Organization for Rare Disorders (NORD), 2017, each year, only 27
individuals per million population are estimated to be diagnosed with carcinoid tumors in the
U.S., amongst whom, only 10% individuals develop carcinoid syndrome. Moreover, it affects
both males and females in equal number. Increasing prevalence of the disease is in turn,
increasing demand for carcinoid syndrome diarrhea treatment devices. This in turn is expected
to fuel growth of the carcinoid syndrome diarrhea treatment market.
      @
https://www.coherentmarketinsights.com/ongoing-insight/carcinoid-syndrome-diarrhea-treatmentmarket-1216
            
, .,    ( ),   .,  
.,     .,  .% .,   , ., 
 ,    .
   
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
 
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
: [email protected]
Author
Alex Huge
Alex Huge339   documents Email
Document
Category
Health and Medicine
Views
1
File Size
135 KB
Tags
diarrhea, Carcinoid Syndrome Diarrhea Treatment Market
1/--pages
Report inappropriate content